Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Volcano’s VH IVUS technology assists atherosclerotic cardiovascular disease studies

Volcano : 03 September, 2008  (Company News)
Volcano’s VH IVUS (Virtual Histology IVUS) is being used in GlaxoSmithKline's IBIS-2 trial (Integrated Biomarker and Imaging Study).
In the study, Volcano's VH IVUS technology demonstrated and quantified compositional changes in atherosclerotic plaque that occurred over time. In IBIS-2, VH IVUS showed compositional changes in the placebo group that suggest continued progression of necrotic core despite standard of care therapy. Use of the novel Lp-PLA2 inhibitor, darapladib, plus standard of care therapy prevented this progression. VH IVUS is a catheter-based technology that creates colourised tissue maps of plaque composition in real-time.

Despite advances in diagnosis and therapy, atherosclerotic cardiovascular disease (CVD) is the number one killer of men and women in the Western world. Principal manifestations of atherosclerotic cardiovascular disease are heart disease and stroke. Atherosclerosis is the underlying mechanism for coronary artery disease, ischemic strokes, and peripheral vascular disease. Although a number of factors contribute to CVD, elevated plasma levels of Lp-PLA2 (lipoprotein-associated phospholipase A2) are associated with an increased risk.

'The results of IBIS-2 indicated that many coronary vessels with mild angiographic disease have large atherosclerotic plaques, which can be identified by VH IVUS. The ability to characterise composition of these lesions can potentially provide a means to examine the natural history of atherosclerosis. This, combined with studies of novel agents that act directly on the plaque, can help increase our understanding of the mechanisms of future clinical events,' commented Patrick Serruys, MD, PhD, professor of medicine, the Erasmus University, and Chairman of the Steering Committee for IBIS-2.

IBIS-2 was a 52 week, 300 participant, international, multicentre, randomised, double-blind, placebo-controlled, parallel group trial of darapladib in subjects with angiographically documented coronary heart disease. The main objectives of the study were to determine the effects of darapladib on composition and biomechanical properties of atherosclerotic plaque, as well as circulating inflammatory biomarkers.

'Current treatments for atherosclerosis include preventative lifestyle modifications and the regulation of physiological and biochemical risk factors such as blood pressure and lipid profile. VH IVUS measures the effects of investigational compounds on plaque composition. We believe that IVUS can be an indispensable assessment tool in the development of a drug candidate that directly affects coronary plaque stability, as opposed to treating symptoms or lipid levels alone,' said Scott Huennekens, president and chief executive officer, Volcano. 'The ability to identify and characterize composition may lead to great advances in CVD drug development, diagnosis, and eventually tailored systemic therapy. The same way a biopsy and other blood and imaging tests can define a cancer treatment plan, we believe that one day Volcano technology could help define a personalized patient by patient strategy for systemic and local therapy that could dramatically improve patient outcomes.'

Volcano's VH IVUS technology uses advanced spectral analysis techniques to allow simplified interpretation of Ultrasound images and provide detailed information on the composition of each patient's atherosclerotic plaques.

The colour VH images show four plaque component types: necrotic core, dense calcium, fibrous and fibro-fatty. VH IVUS images are created using Volcano's imaging console along with the Eagle Eye Gold IVUS imaging catheter. Images are displayed live, in the catheterization laboratory for easy review by the interventional cardiologist and his or her staff while the patient remains on the table. No changes to standard clinical practice are required to employ VH IVUS.

The novel technology provides automated measurement tools to simplify image interpretation and employs a pre-determined colour key to display plaque composition at a specific point in the artery or across a region of interest.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo